以組學為基礎的臨床試驗市場：按階段、研究設計、適應症 - 2023-2030 年全球預測

全球基於組學的臨床試驗市場預計將在 2023 年大幅成長，達到 301 億美元，年複合成長率為 8.32%，預計到 2030 年將達到驚人的 529.2 億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球組學臨床試驗市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.基於組學的臨床試驗的全球市場規模和預測是多少？

2.在預測期內，COVID-19對全球組學臨床試驗市場的阻礙因素與影響為何？

3. 在預測期內，全球基於組學的臨床試驗市場需要投資哪些產品/細分市場/應用/領域？

4. 全球組學臨床試驗市場的競爭策略為何？

5. 全球組學臨床試驗市場的技術趨勢和法律規範是什麼？

6. 全球基於組學的臨床試驗市場主要供應商的市佔率是多少？

7. 哪些型態和策略措施被認為適合進入基於組學的臨床試驗的全球市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • 加大醫藥研發部門投入
    • 全球各種慢性病的罹患率和負擔正在增加。
    • 日益關注個人化醫療和腫瘤學臨床臨床實驗
  • 抑制因素
    • 基於組學的臨床試驗產品價格昂貴
  • 機會
    • 提高消費者意識並採用多組學解決方案
    • 全球合併活動數量激增
  • 任務
    • 有效資料分析的挑戰
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化

第6章 以組學為基礎的臨床試驗市場分階段

• 第一階段
• 第二階段
• 第三階段
• 第四階段

第7章 研究設計的基於組學的臨床試驗市場

• 擴大訪問研究
• 干預研究
• 觀察性研究

第8章 以組學為基礎的臨床試驗市場（按適應症）

• 心臟病學
• 中樞神經系統疾病
• 遺傳疾病
• 免疫學
• 腫瘤學
• 呼吸系統疾病
• 皮膚病

第9章 美洲組學臨床試驗市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第10章 亞太組學臨床試驗市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第11章歐洲、中東和非洲基於組學的臨床試驗市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第12章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第13章上市公司名單

第14章附錄

• 討論指南
• 關於許可證和定價

The Global Omics-Based Clinical Trials Market is forecasted to grow significantly, with a projected USD 30.10 billion in 2023 at a CAGR of 8.32% and expected to reach a staggering USD 52.92 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Omics-Based Clinical Trials Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Omics-Based Clinical Trials Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV. The Phase II is projected to witness significant market share during forecast period.

Based on Study Design, market is studied across Expanded Access Studies, Interventional Studies, and Observational Studies. The Expanded Access Studies is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Cardiology, CNS Diseases, Genetic Diseases, Immunology, Oncology, Respiratory Diseases, and Skin Diseases. The Cardiology is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Omics-Based Clinical Trials Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Omics-Based Clinical Trials Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Omics-Based Clinical Trials Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Omics-Based Clinical Trials Market?

4. What is the competitive strategic window for opportunities in the Global Omics-Based Clinical Trials Market?

5. What are the technology trends and regulatory frameworks in the Global Omics-Based Clinical Trials Market?

6. What is the market share of the leading vendors in the Global Omics-Based Clinical Trials Market?

7. What modes and strategic moves are considered suitable for entering the Global Omics-Based Clinical Trials Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Omics-Based Clinical Trials Market, by Phase, 2022 vs 2030
• 4.3. Omics-Based Clinical Trials Market, by Study Design, 2022 vs 2030
• 4.4. Omics-Based Clinical Trials Market, by Indication, 2022 vs 2030
• 4.5. Omics-Based Clinical Trials Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising investment in the pharmaceutical research and development sector
    • 5.1.1.2. Increasing prevalence and burden of various chronic diseases globally
    • 5.1.1.3. Growing focus on personalized medicine and oncology trials
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of omics-based clinical trials products
  • 5.1.3. Opportunities
    • 5.1.3.1. Upsurging consumer awareness and adoption of multi-omics solutions
    • 5.1.3.2. Proliferation in the number of amalgamation activities across the globe
  • 5.1.4. Challenges
    • 5.1.4.1. Issues relating to effective data analysis
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Omics-Based Clinical Trials Market, by Phase

• 6.1. Introduction
• 6.2. Phase I
• 6.3. Phase II
• 6.4. Phase III
• 6.5. Phase IV

7. Omics-Based Clinical Trials Market, by Study Design

• 7.1. Introduction
• 7.2. Expanded Access Studies
• 7.3. Interventional Studies
• 7.4. Observational Studies

8. Omics-Based Clinical Trials Market, by Indication

• 8.1. Introduction
• 8.2. Cardiology
• 8.3. CNS Diseases
• 8.4. Genetic Diseases
• 8.5. Immunology
• 8.6. Oncology
• 8.7. Respiratory Diseases
• 8.8. Skin Diseases

9. Americas Omics-Based Clinical Trials Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Omics-Based Clinical Trials Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Omics-Based Clinical Trials Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. OMICS-BASED CLINICAL TRIALS MARKET RESEARCH PROCESS
• FIGURE 2. OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2022 VS 2030
• FIGURE 3. OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022 VS 2030 (%)
• FIGURE 5. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2022 VS 2030 (%)
• FIGURE 6. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
• FIGURE 7. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 8. OMICS-BASED CLINICAL TRIALS MARKET DYNAMICS
• FIGURE 9. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. OMICS-BASED CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 17. OMICS-BASED CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. OMICS-BASED CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 5. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 10. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 14. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY CNS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY SKIN DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. CANADA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 33. CANADA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 50. CHINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. INDIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 53. INDIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. ITALY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 105. ITALY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. POLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 117. POLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. QATAR OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 120. QATAR OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. OMICS-BASED CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 149. OMICS-BASED CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 150. OMICS-BASED CLINICAL TRIALS MARKET LICENSE & PRICING